Cargando…

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective

The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrario, Cristiano, Christofides, Anna, Joy, Anil Abraham, Laing, Kara, Gelmon, Karen, Brezden-Masley, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026432/ https://www.ncbi.nlm.nih.gov/pubmed/35448196 http://dx.doi.org/10.3390/curroncol29040222

Ejemplares similares

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019)

Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study
por: Maxwell, Cynthia, et al.
Publicado: (2021)

Gynecologic Symptoms among Hormone Receptor-Positive Breast Cancer Patients on Oral Endocrine Therapy: A Cross-Sectional Study
por: Moskalewicz, Alexandra, et al.
Publicado: (2022)

Cancer and Cardiovascular Disease: The Complex Labyrinth
por: Dent, Susan, et al.
Publicado: (2015)

Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma – significance of potentially retained stemness
por: Yoon, Ju-Yoon, et al.
Publicado: (2020)

Autophagic Heterogeneity in Gastric Adenocarcinoma
por: Yoon, Ju-Yoon, et al.
Publicado: (2021)

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
por: Covelli, Andrea, et al.
Publicado: (2019)

Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
por: McGee, Sharon F., et al.
Publicado: (2022)

Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
por: Abadir, Amir, et al.
Publicado: (2012)

Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study
por: Yoon, Ju-Yoon, et al.
Publicado: (2019)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Mammographic microcalcifications and breast cancer tumorigenesis: a radiologic-pathologic analysis
por: Naseem, Madiha, et al.
Publicado: (2015)

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
por: Gelmon, Karen, et al.
Publicado: (2021)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies
por: Owen, Carolyn, et al.
Publicado: (2022)

Targeted therapeutic options and future perspectives for HER2-positive breast cancer
por: Wang, Jiani, et al.
Publicado: (2019)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_69k9ehp6lv2147vp0q22cluju9